Literature DB >> 25533274

Compressive Optic Neuropathy and Repeat Orbital Decompression: A Case Series.

Courtney Y Kauh1, Shivani Gupta, Raymond S Douglas, Victor M Elner, Christine C Nelson, Leslie M Niziol, Alon Kahana.   

Abstract

PURPOSE: To characterize the presenting characteristics, preoperative clinical activity score (CAS), surgical approach, and visual outcomes in patients with thyroid eye disease undergoing repeat orbital decompression for recurrent or recalcitrant compressive optic neuropathy (CON).
METHODS: The medical records of patients with recurrent or recalcitrant CON undergoing repeat orbital decompressions were retrospectively reviewed. The primary outcome measures included pre- and postoperative Humphrey visual field mean deviation, visual acuity (VA) measured in logarithm of the minimal angle of resolution, color vision measured by Ishihara plates, and presence of relative afferent pupillary defect. Details of the surgical procedure and each patient's CAS at presentation were also recorded.
RESULTS: Six patients, 9 orbits, with a mean preoperative CAS of 3.8 were included in this review. The mean time between initial decompression and presentation to our center for recurrent or persistent CON symptoms was 8.6 years (range, 1 to 15 years). At presentation, the average Humphrey visual field mean deviation was -16.5 (standard deviation: 8.8), improving to -3.8 (2.4) postoperatively with a mean of 9.3 months follow up (mean improvement of 75%). Preoperative VA was 0.34 (0.23) LogMAR, improving to 0.05 (0.10) LogMAR with a mean follow up of 10.4 months. Pre- to postoperative comparisons of clinical measures all showed statistically significant improvement (p < 0.05). Eight eyes presented with decreased VA (any VA < 20/20), 4 with decreased color vision (any color vision < 11), and 1 with a relative afferent pupillary defect, and all these patients demonstrated improvement following repeat orbital decompression.
CONCLUSIONS: In patients with thyroid eye disease, symptoms of recurrent CON occurred up to 15 years following initial orbital decompression underscoring the smoldering, progressive nature of the disease. Repeat decompression that focused on the orbital apex resulted in visual improvement in all 6 patients. Despite clinical evidence of CON, the mean CAS of these patients at presentation was only 3.8, highlighting the importance of close monitoring of patients with thyroid eye disease following decompression regardless of the external manifestations of disease activity.

Entities:  

Mesh:

Year:  2015        PMID: 25533274      PMCID: PMC5036444          DOI: 10.1097/IOP.0000000000000356

Source DB:  PubMed          Journal:  Ophthalmic Plast Reconstr Surg        ISSN: 0740-9303            Impact factor:   1.746


  40 in total

1.  Orbital decompression for severe Graves' ophthalmopathy. Results of a three-wall operative technique.

Authors:  L Bartalena; C Marcocci; F Bogazzi; M Panicucci; G Bruno-Bossio; R Cantini; A Lepri; G Tusini; A Pinchera
Journal:  J Neurosurg Sci       Date:  1989 Oct-Dec       Impact factor: 2.279

2.  Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy.

Authors:  M P Mourits; M F Prummel; W M Wiersinga; L Koornneef
Journal:  Clin Endocrinol (Oxf)       Date:  1997-07       Impact factor: 3.478

3.  Corticosteroids in the treatment of optic nerve involvement associated with thyroid dysfunction.

Authors:  R M Day; F D Carroll
Journal:  Arch Ophthalmol       Date:  1968-03

4.  Clinical classification of Graves' ophthalmopathy. Identification of risk factors for optic neuropathy.

Authors:  S E Feldon; S Muramatsu; J M Weiner
Journal:  Arch Ophthalmol       Date:  1984-10

5.  Graves orbitopathy: correlation of CT and clinical findings.

Authors:  R A Nugent; R I Belkin; J M Neigel; J Rootman; W D Robertson; J Spinelli; D A Graeb
Journal:  Radiology       Date:  1990-12       Impact factor: 11.105

Review 6.  Acute thyroid eye disease (TED): principles of medical and surgical management.

Authors:  D H Verity; G E Rose
Journal:  Eye (Lond)       Date:  2013-02-15       Impact factor: 3.775

7.  Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach.

Authors:  M P Mourits; L Koornneef; W M Wiersinga; M F Prummel; A Berghout; R van der Gaag
Journal:  Br J Ophthalmol       Date:  1989-08       Impact factor: 4.638

8.  Intraorbital injection of rituximab: a new approach for active thyroid-associated orbitopathy, a prospective case series.

Authors:  G Savino; L Balia; D Colucci; R Battendieri; M Gari; S M Corsello; A Pontecorvi; A Dickmann
Journal:  Minerva Endocrinol       Date:  2013-06       Impact factor: 2.184

9.  Apical optic nerve compression of dysthyroid optic neuropathy on computed tomography.

Authors:  J S Kennerdell; A E Rosenbaum; M H El-Hoshy
Journal:  Arch Ophthalmol       Date:  1981-05

10.  Reduction of orbital inflammation following decompression for thyroid-related orbitopathy.

Authors:  Sang-Rog Oh; Jonathan D Tung; Ayelet Priel; Leah Levi; David B Granet; Bobby S Korn; Don O Kikkawa
Journal:  Biomed Res Int       Date:  2013-06-18       Impact factor: 3.411

View more
  4 in total

Review 1.  The effect of orbital radiation therapy on thyroid-associated orbitopathy complicated with dysthyroid optic neuropathy.

Authors:  Yang Wang; Huifang Zhou; Xianqun Fan
Journal:  Front Med       Date:  2017-05-13       Impact factor: 4.592

2.  [Orbital decompression : Indications, technique, results].

Authors:  H-J Welkoborsky; S K Graß; J Küstermeyer; K V Steinke
Journal:  HNO       Date:  2017-12       Impact factor: 1.284

3.  Expert Consensus on the Use of Teprotumumab for the Management of Thyroid Eye Disease Using a Modified-Delphi Approach.

Authors:  Raymond S Douglas; Andrea L Kossler; Jody Abrams; Cesar A Briceño; David Gay; Andrew Harrison; Michael Lee; John Nguyen; Shannon S Joseph; Dianne Schlachter; Jeremy Tan; Judah Lynch; Louisa Oliver; Richard Perry; Shoaib Ugradar
Journal:  J Neuroophthalmol       Date:  2022-03-24       Impact factor: 4.415

4.  Early efficacy of teprotumumab for the treatment of dysthyroid optic neuropathy: A multicenter study.

Authors:  Connie M Sears; Yao Wang; Lucy A Bailey; Roger Turbin; Prem S Subramanian; Raymond Douglas; Kimberly Cockerham; Andrea L Kossler
Journal:  Am J Ophthalmol Case Rep       Date:  2021-05-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.